Department of Surgery, University of Auckland, Auckland, New Zealand.
Colorectal Dis. 2023 Jan;25(1):144-149. doi: 10.1111/codi.16464. Epub 2023 Jan 16.
The primary aim of the study is to describe the variation in the operative and nonoperative management of emergency presentations of colon and rectal cancer in an international cohort. Secondary aims will be to develop a risk prediction model for mortality and primary anastomosis and validate risk criteria of large bowel obstruction (LBO) in patients with previously known colorectal cancer undergoing neoadjuvant chemotherapy or awaiting elective surgery.
This prospective, multicentre audit will be conducted via the student- and trainee-led EuroSurg Collaborative network internationally over 2023 with 90-day follow-up. Data will be collected on consecutive adult patients presenting to the hospital in an unplanned and urgent manner with colorectal cancer (CRC) due to malignant LBO, perforation, CRC-related haemorrhage, or other related reasons. Primary outcome is 90-day mortality. Secondary outcomes include rates of stomas, primary anastomosis, stenting, preoperative imaging, and complications or readmissions.
This protocol describes the methodology for the first international audit on the management of acutely presenting CRC. This study will utilise a large collaborative network with robust data validation and assurance strategies. APOLLO will provide a comprehensive understanding of current practice, develop risk prediction tools in this setting, and validate existing trial results.
本研究的主要目的是描述国际队列中结肠和直肠癌症急诊表现的手术和非手术管理的变化。次要目的是为接受新辅助化疗或等待择期手术的先前已知结直肠癌患者开发死亡率和一期吻合术的风险预测模型,并验证大肠梗阻(LBO)的风险标准。
本前瞻性、多中心审计将通过学生和培训生领导的 EuroSurg 协作网络在 2023 年进行,随访时间为 90 天。数据将收集连续的成年患者,由于恶性 LBO、穿孔、CRC 相关出血或其他相关原因,以非计划和紧急方式出现结肠直肠癌(CRC)。主要结局是 90 天死亡率。次要结局包括造口、一期吻合术、支架、术前影像学和并发症或再入院率。
本方案描述了首次关于急性结直肠癌管理的国际审计的方法学。本研究将利用一个大型协作网络,具有强大的数据验证和保证策略。APOLLO 将全面了解当前的实践情况,在此基础上开发风险预测工具,并验证现有试验结果。